NNP
GSK icon

Nachman Norwood & Parrott’s GSK GSK Stock Holding History

Nachman Norwood & Parrott’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,771
Closed -$177K – 572
2020
Q3 		$177K Buy
+3,771
New +$189K 0.02% 263
2020
Q1 		– Sell
-3,771
Closed -$222K – 233
2019
Q4 		$222K Hold
3,771
– – 0.04% 233
2019
Q3 		$201K Buy
+3,771
New +$194K 0.04% 230
2019
Q2 		– Sell
-3,856
Closed -$201K – 242
2019
Q1 		$201K Buy
+3,856
New +$193K 0.04% 224

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Nachman Norwood & Parrott's GSK Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of GSK (GSK) in Q4 2020, closing a stake of 3,771 shares — an estimated $177K sold.

Nachman Norwood & Parrott first reported a position in GSK in Q1 2019 and held it in 4 quarters. The position peaked at $222K in Q4 2019. 818 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining GSK position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 3,771 GSK shares in Q4 2020, an estimated $177K.
  • Nachman Norwood & Parrott first reported a position in GSK in Q1 2019 and held it in 4 quarters.
  • Nachman Norwood & Parrott's GSK position peaked at $222K in Q4 2019.
  • 818 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.